AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.

Schmid, P, Abraham, J, Chan, S et al. (17 more authors) (2018) AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. In: 2018 ASCO Annual Meeting, 01-05 Jun 2018, Chicago, IL, USA.

Metadata

Authors/Creators:
  • Schmid, P
  • Abraham, J
  • Chan, S
  • Wheatley, D
  • Brunt, M
  • Nemsadze, G
  • Baird, R
  • Park, YH
  • Hall, P
  • Perren, T ORCID logo https://orcid.org/0000-0001-8472-8856
  • Stein, RC
  • László, M
  • Ferrero, J-M
  • Phillips, M
  • Conibear, J
  • Sarker, S-J
  • Prendergast, A
  • Cartwright, H
  • Mousa, K
  • Turner, NC
Dates:
  • Published: 20 May 2018
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 02 Nov 2020 11:32
Last Modified: 02 Nov 2020 11:32
Status: Published
Identification Number: https://doi.org/10.1200/jco.2018.36.15_suppl.1007
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)